Background: Reducing near-fatal asthma exacerbations is a critical problem in asthma management.
device companies. This was an investigatorinitiated clinical study with operational and technical support provided by the FBRI.
Results: Three distinct clusters of symptoms were defined employing the self-reporting of a visual analogue scale. Cluster A (42.1%): rapid worsening within 7.4 hours from moderate attack to admission, young to middle-aged patients with low Body mass index and tendency to depression who had stopped anti-asthma medications, smoked, and hypersensitive to environmental triggers and furred pets. Cluster B (40.0%): fairly rapid worsening within 48 hours, mostly middle-aged and older, relatively good inhaled corticosteroid (ICS) or ICS/long-acting beta-agonist (LABA) compliance, and low perception of dyspnea. Cluster C (17.9%): slow worsening over 10 days before admission, high perception of dyspnea, smokers, and chronic daily mild-moderate symptoms. There were no differences in overuse of short-acting beta-agonists, baseline asthma severity, or outcomes after admission for patients in these 3 clusters.
Conclusion: To reduce severe or life-threatening asthma exacerbation, personalized asthma management plans should be considered for each cluster. Improvement of ICS and ICS/LABA compliance and cessation of smoking are important in cluster A.
To compensate for low perception of dyspnea, asthma monitoring of peak expiratory flow rate and/or exhaled nitric oxide would be useful for patients in cluster B.
Avoidance of environmental triggers, increase usual therapy, or new anti-type 2 response-targeted therapies should be considered for cluster C. 1 Frequent asthma exacerbation is a risk factor associated with progression to severe disease and excessive decline in lung function. 2 Severe exacerbation is recognized as an indication for evaluating the required level of interventional asthma management to reduce the potential risk of death. [3] [4] [5] [6] [7] [8] Using cluster analysis, many studies have described the heterogeneity of severe asthma symptoms during nonexacerbation periods. 1, [9] [10] [11] [12] However, to the best of our knowledge, no studies have reported on the heterogeneity of patient factors preceding worsening symptoms leading to severe or life-threatening exacerbation in a real-world setting.
Previous reports to date have relied on information extracted by physicians from limited medical histories and on information provided by relatives or friends of patients who died from severe asthma. [3] [4] [5] Other studies have shown that short-acting beta-agonist (SABA) usage was increased from around 5 days preceding emergency hospitalization. 13, 14 However, these previous data were from strictly controlled clinical trials with good compliance to inhaled corticosteroid (ICS) or ICS/long-acting beta-agonist (LABA) use, while in general clinical practice, variable asthma drug compliance and smoking habits prevail as confounding factors. To accurately predict and reduce exacerbation, it is necessary to determine the factors influencing the pattern of exacerbation in a real-world setting and adjust management strategies for each patient accordingly.
We recently performed a nationwide, prospective, multicenter study in which patients admitted for severe or life-threatening asthma were recruited at emergency hospitals throughout Japan. 15 The results demonstrated that significant heterogeneity exists among patients with severe or life-threatening asthma exacerbation. We further estimated trajectories of asthma symptoms using k-means for longitudinal data in this study.
Inaccurate assessment of asthma severity often delays the provision of an appropriately intensive treatment, consequently leading to hospital admission or even death. In recent real-world adult asthma studies, symptoms assessed by visual analogue scale (VAS) scoring have been proposed as potentially reliable tools for managing patients more effectively and for predicting uncontrolled asthma at home or the general practitioner's office. [16] [17] [18] To predict, prevent, and manage severe or life-threatening asthma exacerbation, we herein assessed serial VAS scores from the 14 days before emergency hospitalization and sought to identify predictors of asthma worsening using cluster analysis.
| METHODS

| Study setting
This study was a secondary analysis of a previously reported prospective, multicenter, observational study of patients with TANAKA ET AL.
| 1111 severe or life-threatening asthma exacerbation. 15 In the previous study 15 , we did not analyze the serial asthma symptom using 10 cm VAS scores. This study was conducted by the Innovative Asthma Association (IAA), a nationwide group performing research across Japan. Patients were recruited from 17 hospitals between October 2011 and December 2012. Briefly, all eligible patients met the following criteria: (i) >16 years of age; (ii) requiring hospitalization due to severe or life-threatening asthma attacks with SpO 2 <90% on room air at the time of hospitalization or emergency transport before treatment, and (iii) no heart failure, pneumonia, pneumothorax, or other pulmonary diseases on X-ray.
Severe or life-threatening exacerbation was defined according to the Japanese Society of Allergology guidelines, 19 that is, an inability to move because of dyspnea, difficulty in speaking, and the following objective findings: peak expiratory flow (PEF) <60%, SpO 2 <90%, partial pressure of oxygen in arterial blood (PaO 2 ) ≤60 mm Hg, and partial pressure of carbon dioxide in arterial blood (PaCO 2 ) ≥45 mm Hg.
The study was reviewed and approved by the Ethics Committee of Sapporo Medical University (No. . The study protocol is registered with the University Hospital Medical Information Network in Japan (number 000006448). 
| Questionnaire
| Serial VAS
Self-administered serial VAS of asthma symptoms comprising a 10cm-long vertical segment was completed retrospectively, daily from 14 days before admission (day À14) to day À3, and then at À60, À48, À36, À24, À12, À6, and À3 hours, and finally at 0 hours (on admission). The patient was asked to indicate his/her actual perception of asthma symptoms by marking a point along the segment. In this study, a score of 0 corresponded to optimal symptom-free breathing, whereas 10 corresponded to the most severe asthmatic symptoms. Mild asthma exacerbation (0 < VAS ≤ 3.3) was defined as "wheeze or cough," "can lie down," and "daily life not disturbed"; moderate asthma exacerbation (3.3 < VAS ≤ 6.6) was defined as "cannot lie down," "mildly disturbed daily life," and "mild dyspnea sensation"; finally, severe exacerbation (6.6 < VAS ≤ 10) was defined as "cannot move," "cannot speak," and "strong dyspnea." These "mild," "moderate," and "severe" categories were depicted by dotted lines on the VAS score sheet (Figures S1 and S2).
| Statistical analysis
Clusters (or trajectories) for the longitudinal VAS scores were estimated using k-means for longitudinal data. [21] [22] [23] This nonparametric procedure partitions cases into clusters. Each case is first assigned arbitrarily to 1 initial cluster. Next, each case is reassigned to the neighborhood cluster based on the center (average) of each cluster.
The operation is repeated until that there is no change by mean adjustment in the clusters. This process to convergence is then repeated. The best cluster number is determined by clinical interpretability and a criterion that maximizes a ratio computed by dividing between variance by within variance (ie, maximizing the homogeneity within clusters and maximizing the differences between clusters). Missing VAS scores (<4% of total) were appropriately treated by linear interpolation. The interpolated VAS scores were divided by 10 and subjected to log-log transformation, and these values were then used in the cluster analysis.
Additionally, differences in characteristics at admission between clusters were tested using the Kruskal-Wallis test for continuous variables and the chi-square test for categorical variables. To construct a decision tree for identifying specific clusters, we performed a tree-based recursive partitioning by conditional inference. Analyses were performed using R version 3.3.2 (R Foundation, Vienna, Austria) with the functions "kml" (package: kml) and "ctree" (package: party).
| RESULTS
Patients meeting the eligibility criteria during the study period numbered 223 recruited from 17 hospitals throughout Japan. 15 Thirtythree patients were excluded because the attending physicians considered it inappropriate to include them in the study. Thus, cluster analysis was performed on 190 patients ( Figure 1 ). Of these, 50% had a history of prior hospitalization for asthma exacerbation (Table 1) , and all of them had been admitted to the hospital emergency room with SpO 2 <90%, allowing us to exclude psychosomatic exacerbation and other diseases such as vocal cord dysfunction. The 190 asthmatic patients were clustered into 3 separate groups according to serial VAS scores. These were characterized by rapidly (cluster A), fairly rapidly (cluster B), and slowly (cluster C) worsening asthma symptoms. Trajectories of changes in median VAS values of the 3 clusters in the total of 190 subjects from the day À14 up to hospital admission are shown in Figure 2 . Asthma symptoms by VAS scoring gradually worsened from the day À8 to À6 before admission. The median VAS score reached 3.3 cm approximately 24 hours before subsequent admission in all 190 patients. A VAS score of 3.3 cm represents the border between mild and moderate exacerbations. Histograms of the VAS score at day À6, À6 hours, À3 hours before admission, and 0 hours (at admission) for each cluster are depicted in Figure 3 . Demographic characteristics, comorbidities, usual symptom triggers, current asthma condition, current triggers, and drug usage of patients in these 3 clusters are shown in Tables 1,   2 , and S1.
The characteristics of cluster A were a rapidly worsening state (n = 80, 42.1%); median VAS score reached 3.3 or 6.6 cm by 7.4 or 2.7 hours before admission, respectively ( Figure 2 ). The VAS score at admission was 10 cm in 100% of patients in this cluster (Figure 3) . The trigger for current exacerbation given as "stopped using anti-asthma medication" was most frequent in cluster A relative to the other 2 clusters (P = .003, Table S1 ). Patients in cluster A were lean (25% with a body mass index <18.5), young or middle-aged (mean 51 year), had poor compliance with anti-asthma medication (only 36% of patients used their ICS 4 or more days a week), were current smokers (53%), and were allergic to furred pets, mites, and moths, sensitive to cold air or other climate variations (Tables 1, 2 and S1). It was founded a tendency (P = .071) for cluster A to have more psychological diseases; 6 of depression and 1 anxiety, as compared with cluster B and C (Table 1) . A tree diagram separating cluster A from B and C is shown in Figure S3 .
In contrast, patients in cluster B had rapid worsening (n = 76, 40.0%) with the median duration of 48 and 8.7 hours from the time of the VAS score reaching 3.3 and 6.6 cm, respectively, to the time of admission ( Figure 2 ). They were middle-aged or older (63 year), with comorbidities including hyperlipidemia (25%) and high hemoglobin A 1c (P = .022), and had relatively good ICS or ICS/LABA compliance, but with a reduced sensation of dyspneic deterioration (Tables 1 and S2 ). Even at admission, 45% perceived mild-to-moderate dyspnea (Figure 3) , with the lowest arterial blood oxygen concentration of all 3 clusters, at a mean PaO 2 of 72 Torr (Table S1 ). These characteristics and the exacerbation status of patients in the 3 clusters are summarized in Table 3 . Additionally, it can be stated that there were no differences among these patients regarding maximum oxygen inhalation dose, duration of supplemental oxygen, or duration of hospitalization (data not shown). There was no seasonal variation of the frequency of each cluster (data not shown).
| DISCUSSION
The work presented here is a secondary analysis of our previous study, 15 representing details of the events that occur shortly before and during severe or life-threatening asthma exacerbation. Our results document a gradual increase in the VAS score for asthmatic symptoms over 6-8 days before hospital admission, to hospital, leading to moderate severity (VAS > 3.3) at 24 hours before admission in all 190 patients surveyed ( Figure 2 ). These results are consistent with a previous study by Tattersfield et al. 13 reported a gradual decline PEF over 5-7 days associated with severe exacerbation. These investigators also reported that changes in PEF, asthma symptoms, and use of rescue beta-agonists before exacerbation occurred in a parallel manner.
Herein, using serial VAS scores of asthma symptoms, we have identified 3 groups of patients with diverse backgrounds but showing distinct characteristics leading up to severe or life-threatening exacerbation. As assessed in a real-world setting rather than a controlled trial, these patients fell into 3 groups with rapid, fairly rapid, or slow progression. We found that there were no differences among these 3 clusters in overuse of SABA before admission, baseline asthma severity, comorbid chronic obstructive pulmonary disease (COPD), or outcome after hospital admission. Interestingly, there were differences in ICS or ICS/LABA compliance, perception of dyspnea, and baseline hypersensitivity to environmental stimuli. These findings imply that optimal personalized management regimens, aimed at preventing severe or life-threatening asthma exacerbation in normal daily life, would differ even among patients within these clusters.
We found that patients assigned to cluster A showed rapid worsening just hours before moderate asthma attack and required emergency admission. Nonetheless, their subjective perception of asthma symptoms was essentially accurate, as reflected by their VAS score being 10 cm on admission for all patients in cluster A (Figure 3 ). | 1115 consistent with the literature. 25, 26 For these patients, objective measurements, that is, daily monitoring of PEF 27 or fractional exhaled nitric oxide concentration, may be useful for early detection of exacerbation and recognizing the patient 0 s actual objective asthmatic status.
Finally, cluster C consisted of patients gradually worsening from VAS = 3.3 and VAS = 6.6 over approximately 10 days and 12 hours, respectively. The most characteristic features of this cluster were mild-to-moderate asthmatic symptoms present daily despite relatively good compliance with ICS. Severe symptoms (VAS > 6.6) were already present in 94% of patients 6 hours before admission (Figure 3 ).
Patients falling into this cluster are unique in that although they had strong perceptions of dyspnea, they failed to seek medical attention before respiratory failure, likely because they had become accustomed to experiencing mild-to-moderate symptoms every day. Patients in this cluster shared hypersensitivity to environmental triggers and furred pets with cluster A, as well as smoking. As shown in Table 1 , baseline severity of asthma in cluster C patients was not different from the other 2 clusters. Only 29% of cluster C patients had severe persistent asthma poorly controlled by the current standard of care medication; for this subgroup, T-helper type 2 response-targeting therapies or other new drugs 28 might be considered. However, in most patients in this cluster, avoidance of environmental triggers, education on the necessity for even better ICS or ICS/LABA compliance, and changing to higher dose ICS or ICS/LABA may be effective.
Baseline disease severity of the patients in our study was mild intermittent in 34%, mild persistent in 18%, moderate persistent in 26%, and severe persistent in the remaining 22%, as shown in Table 1 .
Consistent with previous reports, these findings indicate that severe exacerbation or near-fatal asthma is not related to baseline asthma severity. 29, 30 Surprisingly, 52% of the adult patients in this real-life setting had mild asthma, and their baseline disease severities did not differ among the 3 clusters (Table 1 ). In a Japanese study of asthma deaths in adults, 20 the most frequent degree of baseline asthma severity was "severe" in 39.2% of cases, followed by "moderate" in 33.0%.
On the other hand, in a UK pediatric cohort study, half of asthma deaths were in patients with mild or moderate asthma. 31 It was also reported that near-fatal or severe asthma exacerbations show agerelated differences in clinical presentation. 32, 33 In our present study, relative to younger adults (<41 years), there was a trend toward increasing VAS symptom scores in middle-aged and elderly patients (≥41 years) between day À8 days and À24 hours before hospitalization. However, there were no differences over the period 12 hours before admission among our 3 groups (data not shown). The clustering was not affected by baseline disease severity or age.
We also found a tendency for patients in cluster A to have more psychological diseases; depression and anxiety, as comparing with cluster B and C ( [34] [35] [36] Psychosocial stress is well known to evoke asthma exacerbation, either as triggers or as covariates of worse outcomes, 34 and strain or stress is clinical setting. It has also been reported that changes in asthma symptom scores, PEF, and use of rescue beta-agonists before exacerbation showed parallels. 13 Third, in this study we could not address the influence of ethnicity upon our cluster, because all participants are one race of Japanese.
In conclusion, we herein identified 3 distinct clusters of worsen- 
